MCO-010 demonstrated positive topline results for vision restoration in patients with advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.
The multicenter, randomized, double-masked, sham-controlled phase 2b RESTORE clinical trial included 18 participants with severe vision impairment due to retinitis pigmentosa who received one intravitreal injection of the multi-characteristic opsin optogenetic therapy compared with nine participants who received a sham intravitreal injection.
Of the 18 participants treated with MCO-010, 88.9% experienced a clinically